Application of SLC4A11 in targeted therapy and prognosis prediction of ovarian cancer

Through detection and inhibitors of the SLC4A11 gene, the problems of early screening and drug resistance of ovarian cancer are solved, new treatment methods are provided, and the prognosis of ovarian cancer patients is improved, and there is significant economic potential and market demand.

CN119061139APending Publication Date: 2024-12-03JINSHAN HOSPITAL AFFILIATED TO FUDAN UNIV (EYE DISEASE PREVENTION & TREATMENT CENT OF JINSHAN DISTRICT RES CENT FOR CHEM INJURY EMERGENCY & CRITICAL MEDICINE OF SHANGHAI MUNICIPAL HEALTH COMMISSION)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410938395.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-13
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art lacks effective means of early screening and diagnosing ovarian cancer, and patients are resistant to standard chemotherapy drugs, resulting in recurrence and poor prognosis, and lack of targeted drugs to inhibit the progression of ovarian cancer.

Method used

Using the SLC4A11 gene as a biomarker and target, a kit is provided for predicting the prognosis of ovarian cancer, to detect the expression level of SLC4A11 gene and to develop its inhibitors to inhibit the proliferation, migration, invasion and apoptosis of ovarian cancer cells.

Benefits of technology

Through the detection and inhibitor of the SLC4A11 gene, it can improve the prognosis of ovarian cancer patients, provide a new potential treatment method, and effectively solve the clinical treatment problems of epithelial ovarian cancer, with significant economic potential and market demand.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061139A_ABST
    Figure CN119061139A_ABST
Patent Text Reader

Abstract

The invention relates to application of SLC4A11 in targeted therapy and prognosis prediction of ovarian cancer. The invention finds that the expression of the SLC4A11 in an ovarian cancer patient sample is increased, and the SLC4A11 is verified in the ovarian cancer patient sample and an ovarian cancer cell line. Animal experiments further prove that the targeted SLC4A11 can inhibit the growth of ovarian cancer. Besides, after the SLC4A11 is knocked down in the ovarian cancer cells, the apoptosis level of the ovarian cancer cells is increased, and after the overexpression of the SLC4A11, the apoptosis level of the ovarian cancer cells is reduced, which indicates that the knockdown of the SLC4A11 can promote the death of the ovarian cancer cells. The invention provides a new therapeutic target for treatment and prognosis prediction of ovarian cancer, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the use of SLC4A11 in targeted therapy and prognosis prediction of ovarian cancer. Background Art

[0002] In my country, the annual incidence of ovarian cancer ranks third among female reproductive system tumors, after cervical cancer and uterine body malignant tumors, and shows an increasing trend year by year. The mortality rate ranks first among female reproductive tract malignant tumors, and it is a malignant tumor that seriously threatens women's health.

[0003] Ovarian malignancies include a variety of pathological types, the most common of which is epithelial cancer, which accounts for about 80% of ovarian malignancies. Due to the lack of clinical symptoms in the early stages of the disease, 70% of patients are in the late stages when they seek medical treatment, which seriously affects the patient's prognosis. The current standard first-line treatment for ovarian cancer is tumor reduction surgery followed by platinum-based combined with paclitaxel chemotherapy. The initial treatment effect is good, but 80% of patients face recurrence and drug resistance. Therefore, early diagnosis and resolution of recurrence and drug resistance have become urgent problems to improve the prognosis of ovarian cancer patients.

[0004] Among them, for paclitaxel resistance in ovarian cancer, researchers have explored a variety of mechanisms that mediate paclitaxel resistance in ovarian cancer, including 1) changes in microtubules, 2) upregulation of p-gp, 3) overexpression of anti-apoptotic proteins or inhibition of apoptotic proteins, and 4) changes in cytokines and signaling pathways. For this reason, several methods for reversing paclitaxel resistance in ovarian cancer have also been proposed, but there is currently no effective adjuvant drug available clinically to reverse paclitaxel resistance in ovarian cancer.

[0005] However, there is no reliable means of early screening and diagnosis of ovarian cancer. Most of the examination methods need to be used in combination to accurately screen the early onset of ovarian cancer. Therefore, there is a lack of effective early screening methods. The standard treatment for ovarian cancer is surgery assisted by platinum-based chemotherapy combined with paclitaxel. Patients often achieve significant results in the early stages of treatment, but most will relapse within 2 years. Recurrent epithelial ovarian cancer is resistant to almost all chemotherapy drugs, which greatly limits the clinical efficacy and application scope of chemotherapy. It is also the main reason for the failure of ovarian cancer treatment. Therefore, it is necessary to develop more drugs that effectively inhibit the progression of ovarian cancer, such as targeted drugs. Summary of the invention

[0006] In view of the deficiencies of the prior art, the present invention provides the use of SLC4A11 in targeted therapy and prognosis prediction of ovarian cancer.

[0007] In a first aspect, the present invention provides a biomarker for predicting the prognosis of ovarian cancer patients, wherein the biomarker is the SLC4A11 gene.

[0008] In a second aspect, the present invention provides the use of the SLC4A11 gene as a diagnostic marker in the preparation of an ovarian cancer prognosis diagnostic reagent or kit.

[0009] In a third aspect, the present invention provides the use of a reagent for detecting the expression level of the SLC4A11 gene in ovarian cancer patients in the preparation of an ovarian cancer prognosis diagnostic reagent or kit.

[0010] As a preferred example, the expression level of SLC4A11 is reduced in patients with ovarian cancer with a better prognosis.

[0011] More preferably, the reagent for detecting the expression level of the SLC4A11 gene is selected from primers that specifically amplify the SLC4A11 gene; or probes that specifically recognize the SLC4A11 gene or its transcript; or antibodies that specifically resist the SLC4A11 protein.

[0012] In a fourth aspect, the present invention provides use of an inhibitor of SLC4A11 in the preparation of a drug for treating ovarian cancer.

[0013] As a preferred example, the siRNA targeting the SLC4A11 gene.

[0014] More preferably, the siRNA is shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3.

[0015] In a fifth aspect, the present invention provides use of an inhibitor of SLC4A11 in preparing a reagent, wherein the reagent is used for:

[0016] a) inhibiting the proliferation of ovarian cancer cells;

[0017] b) inhibiting the migration of ovarian cancer cells;

[0018] c) inhibiting ovarian cancer cell invasion; or

[0019] d) Promote apoptosis of ovarian cancer cells,

[0020] The inhibitor is selected from antisense nucleic acids that use SLC4A11 protein or its transcript as target sequence and can inhibit its protein expression or gene transcription; or constructs that can express or form the antisense nucleic acid.

[0021] In a sixth aspect, the present invention further provides a pharmaceutical composition for treating ovarian cancer, the pharmaceutical composition comprising an inhibitor of SLC4A11 and a pharmaceutically acceptable carrier.

[0022] The present invention has the advantages that:

[0023] 1. The entry point is close to the clinic. The purpose of the present invention is clear, which is to solve the practical problems that plague the treatment of epithelial ovarian cancer in the clinic. Starting from the shortcomings of current treatment methods, a new potential treatment method has been invented. If it can be put into clinical practice one day, it can improve the current situation in a targeted manner, thereby benefiting a large number of patients.

[0024] 2. The guiding concept is novel. The present invention combines the latest and most advanced basic research results at home and abroad, puts forward a creative hypothesis, and proves the practical feasibility of the hypothesis based on sufficient experiments.

[0025] 3. It has great economic potential. The present invention focuses on the actual clinical problems with broad market demand. Currently, there are many patients with epithelial ovarian cancer, and the treatment methods need to be improved urgently. Therefore, once the present invention is successfully transformed, it will obtain good market benefits. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Attached Figure 1 A: The expression level of SLC4A11 was detected in tissue samples of 5 non-ovarian cancer patients and 15 ovarian cancer patients; B: Statistical graph of immunohistochemical scoring. C: qRT-PCR experiment verified the expression level of SLC4A11 mRNA in three human epithelial ovarian cancer cell lines and normal ovarian epithelial cells; D: Western blot experiment verified the expression level of SLC4A11 protein in three human epithelial ovarian cancer cell lines and normal ovarian epithelial cells; E: Statistical graph of D, n = 3, statistical method is unpaired t test; FG: KM plotter database analysis of the relationship between SLC4A11 and progression-free survival (Progression free survival) of ovarian cancer patients; H: Overall survival (OS) prognostic data analysis of TCGA database. Data are presented as mean ± SD. ns, not statistically significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

[0027] Attached Figure 2A: qRT-PCR assay to detect the efficiency of overexpression of SLC4A11 in OVCAR-3 and A2780 cells by transfection of pcDNA3.0-SLC4A11 plasmid, n=3; B: Western blot assay to detect the efficiency of overexpression of SLC4A11 in OVCAR-3 and A2780 cells by transfection of pcDNA3.0-SLC4A11 plasmid, n=3; C: Statistical graph of B; D: qRT-PCR assay to detect the efficiency of knockdown of SLC4A11 by three siRNAs in OVCAR-3 and A2780 cells; E: qRT-PCR assay to detect the efficiency of stable knockdown of SLC4A11 by lentiviral infection in OVCAR-3 and A2780 cells. n=3; F: Western blot assay to detect the efficiency of stable knockdown of SLC4A11 by lentiviral infection in OVCAR-3 and A2780 cells. n = 3; G: Statistical graph of F. The statistical method for two groups of data was unpaired t test; the statistical method for four groups of data was one-way analysis of variance followed by Turkey's two-two test. P-value < 0.05 was considered statistically significant.

[0028] Attached Figure 3 A: Cell viability at different time points was detected in lentiviral-infected OVCAR and A2780 cells with stable knockdown and parental OVCAR-3 and A2780 cells; B: Cell viability at different time points was detected after overexpression of SLC4A11 in OVCAR-3 and A2780 cells; C: EdU assay was performed in lentiviral-infected OVCAR and A2780 cells with stable knockdown and parental OVCAR-3 and A2780 cells, D: Statistical graph of C; E: EdU assay was performed after overexpression of SLC4A11 in OVCAR-3 and A2780 cells; F: Statistical graph of E. n = 3, data are presented as mean ± SD, statistical method was unpaired t test, P-value < 0.05 was considered statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

[0029] Attached Figure 4 A: Cell apoptosis assay after overexpression of SLC4A11 in OVCAR-3 and A2780 cells; B: Cell apoptosis assay after knockdown of SLC4A11 in OVCAR-3 and A2780 cells. n = 3, data are presented as mean ± SD, statistical method was unpaired t test, P-value < 0.05 was considered statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

[0030] Attached Figure 5A: Tumor volume of two groups after nude mouse tumor formation experiment (shNC is the group injected with A2780 cell suspension; shSLC4A11 is the group injected with lentivirus-infected A2780 cell suspension with stable knockdown of SLC4A11); B: Statistical graph of the volume and weight of tumor tissues in two groups. n = 5, data are presented as mean ± SD, statistical method is unpaired t test, P-value < 0.05 is considered statistically significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. DETAILED DESCRIPTION

[0031] The technical content of the present invention is further described below in conjunction with the examples: The following examples are illustrative, not restrictive, and the protection scope of the present invention cannot be limited by the following examples. The test methods used in the following examples are usually based on conventional conditions or conditions recommended by the manufacturer unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0032] Example 1 Cell experiment

[0033] 1. Cell culture

[0034] OVCAR-3, SK-OV-3, A2780 are human epithelial ovarian cancer cell lines, and IOSE-80 is a human normal ovarian epithelial cell, which is used in the cell experiment part of the present invention, wherein IOSE-80 cells are purchased from Shanghai Zhongqiao Xinzhou Biotechnology Co., Ltd., and A2780 cells, SK-OV-3 cells and OVCAR-3 cells are all purchased from Shanghai Seou Biotechnology Co., Ltd. SK-OV-3 and A2780 cell lines are cultured in DMEM medium supplemented with 10% fetal bovine serum, and OVCAR-3 and IOSE-80 cell lines are cultured in PRMI-1640 medium supplemented with 20% fetal bovine serum.

[0035] 2. Plasmid and siRNA transfection experiments

[0036] The cells to be transfected were plated in a 6-well plate and cultured for 24 hours, after which the transfection reagent and 2.5 μg of plasmid or 5 μL of siRNA were added. After standing in the incubator for 6 hours, the old culture medium was removed, new culture medium was added, and cultured for another 48 hours before conducting subsequent experiments.

[0037] 3. Western blot

[0038] Prepare the cell protein sample that has been extracted with SDS in advance, perform electrophoresis on 8% SDS-PAGE gel, transfer to PVDF membrane, and incubate with the corresponding protein antibody at 4°C overnight. The next day, incubate with the corresponding HRP-labeled secondary antibody at room temperature for 1 hour and expose to light for development.

[0039] 4. Cell proliferation assay

[0040] 48 hours after transfection, the cells were plated in a 96-well plate at a density of 7000 cells / well. After 6 hours of attachment, 100 μl of Cell Counting Kit-8 (CCK-8) reagent was added to each well. After incubation at 37 degrees Celsius for 1 hour, the absorbance at 450 nm was read on a microplate reader and calculated as the cell viability value at 0 hours. The absorbance was then tested at 24, 72, and 96 hours, and the results were statistically analyzed.

[0041] 5. Apoptosis Experiment

[0042] 24 hours after transfection, paclitaxel or no paclitaxel was added to the corresponding groups respectively. After 4 hours, the cells were collected and washed twice with PBS. The 10x binding buffer in the BD apoptosis kit was configured to 1x. 100 μl of cells were resuspended and transferred to a flow tube. 1 μl of Annexin V and 2 μl of PI were added. After incubation for 15 minutes, 400 μl of 1x binding buffer was added to make up to 500 μl, and the apoptosis rate was detected by flow cytometry.

[0043] 6. qPCR

[0044] Collect cells, extract total RNA from cells using RNA extraction kit, perform qPCR after reverse transcription. The reagent used is BeyoFast TM Probe qPCRMix (2X, Low ROX), take 7.5μl, DEPC water 5.1μl, front primer 0.45μl, back primer 0.45μl, add 1.5μl of reverse transcription product, use qPCR machine to collect ct value, analyze and process data.

[0045] 7. Results and Analysis

[0046] We used 379 ovarian cancer patient samples from the Cancer Genome Atlas (TCGA) database and 88 normal ovarian cancer tissue samples from the Genotype-Tissue Expression (GTEx) database to analyze and screen differentially expressed genes, and found that SLC4A11 was expressed more frequently in ovarian cancer patient samples. Subsequently, we stained SLC4A11 in the collected human ovarian cancer samples and paraffin sections of non-cancerous ovarian tissues. The results showed that the immunohistochemical score of SLC4A11 in human ovarian cancer tissue samples was higher than that in paraffin sections of non-cancerous ovarian cancer tissues. Figure 1AB). qPCR and Western blot experiments were performed on three ovarian cancer cell lines (OVCAR-3, SK-OV-3, A2780) and normal ovarian epithelial cells (IOSE-80). The results showed that SLC4A11 was upregulated in human epithelial ovarian cancer cell lines compared with normal ovarian epithelial cells. The expression levels of SLC4A11 mRNA and protein in ovarian cancer cell lines were higher than those in normal ovarian epithelial cells ( Figure 1 CE). The prediction results of the K-Mplotter online database showed that patients with low SLC4A11 expression had a longer progression-free survival than those with high SLC4A11 expression ( Figure 1 FG); The results of the overall survival prognosis data analysis of the TCGA database showed that the overall survival of patients with low SLC4A11 expression was longer than that of ovarian cancer patients with high SLC4A11 expression ( Figure 1 H).

[0047] SLC4A11 was overexpressed in ovarian cancer cells by transfection with pcDNA3.1-SLC4A11 plasmid. Figure 2 AD); transfected with siRNA to knock down SLC4A11 (Table 1), silenced the expression level of SLC4A11 in ovarian cancer cell lines ( Figure 2 EG). The experimental results showed that the proliferation rate of ovarian cancer cells in the SLC4A11 knockdown group was lower than that in the non-knockdown group, and the proliferation rate of ovarian cancer cells in the SLC4A11 overexpression group was higher than that in the non-overexpression group, indicating that overexpression of SLC4A11 can promote the proliferation of ovarian cancer cells ( Figure 3 AF).

[0048] In addition, knocking down SLC4A11 in ovarian cancer cells increased the apoptosis level of ovarian cancer cells, while overexpressing SLC4A11 reduced the apoptosis level of ovarian cancer cells, indicating that knocking down SLC4A11 can promote the death of ovarian cancer cells ( Figure 4 AB).

[0049] Table 1 siRNA sequences of SLC4A11

[0050]

[0051] (Note: In the submitted sequence listing, u in RNA is replaced by t according to the requirements of ST.26)

[0052] Example 2 Animal Experiment

[0053] 1. Experimental Animals

[0054] Ten four-week-old female nude mice were purchased from Beijing Spectrum Biotechnology Co., Ltd. and raised in an SPF animal room. One week later, 1×10 ovarian cancer cell suspension was inoculated on the back of the nude mice.7 / 100μL, wait for one week, observe whether the tumor is formed, measure the weight and tumor size of the nude mice every other day, and measure for a total of 3 weeks. Then, the nude mice were anesthetized by intraperitoneal injection of sodium pentobarbital (100mg / kg), and the nude mice were killed to collect the tumor tissue, and the weight and size were measured. The tumor tissue was divided into two parts, one part was immersed in paraformaldehyde for paraffin embedding; the other part was quickly frozen in liquid nitrogen and stored in a -80℃ refrigerator for RNA and protein extraction.

[0055] 2. Reagents

[0056] Reagents and their manufacturers

[0057]

[0058] 3. Experimental methods

[0059] 3.1 Grouping

[0060] Ten four-week-old female nude mice were kept in an SPF animal room for one week and then randomly divided into two groups, 7 in each group, namely the sh-NC group and the sh-SLC4A11 group. They were then ear-tagged and weighed. The NC group was subsequently injected with A2780 ovarian cancer cell suspension, and the Sh group was subsequently injected with A2780 (A2780-sh-SLC4A11) cell suspension that knocked down SLC4A11 by lentivirus infection.

[0061] 3.2 Establishment of animal model

[0062] When the A2780-sh-NC and A2780-sh-SLC4A11 cells grew to a suitable density, the cells were collected by trypsin digestion and counted. Then, 1×10 cells were added to each cell. 7 Prepare the injection solution with serum-free medium at a concentration of 100 μL / 100 μL, place on ice, and complete the injection as soon as possible. When injecting the cell suspension, select the back of the nude mouse for injection.

[0063] 3.3 Detection indicators

[0064] One week after injection, the formation of tumors was observed, and the body weight and tumor volume of nude mice were measured every other day for a total of 3 weeks.

[0065] 4. Results

[0066] The results of the nude mouse tumor formation experiment are shown in Figure 5 AB, Compared with the control group, the tumor tissue and weight of nude mice treated with knockdown SLC4A11 were smaller, further indicating that targeting SLC4A11 can inhibit the growth of ovarian cancer.

[0067] From the above results, it can be seen that the expression level of SLC4A11 is increased in ovarian cancer patients, and higher levels of SLC4A11 are associated with poor prognosis in ovarian cancer patients. Knocking down SLC4A11 can inhibit the growth of ovarian cancer in vivo and in vitro, indicating that SLC4A11 is a potential target for ovarian cancer treatment.

[0068] The preferred specific embodiments of the present invention are described in detail above. It should be understood that ordinary technicians in the field can make many modifications and changes based on the concept of the present invention without creative work. Therefore, all technical solutions that can be obtained by technicians in the technical field based on the concept of the present invention through logical analysis, reasoning or limited experiments on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. A biomarker for predicting the prognosis of patients with ovarian cancer, It is characterized in that The biomarker is the SLC4A11 gene.

2. Application of SLC4A11 gene as a diagnostic marker in the preparation of ovarian cancer prognosis diagnostic reagents or kits.

3. Use of a reagent for detecting the expression level of the SLC4A11 gene in ovarian cancer patients in the preparation of an ovarian cancer prognostic diagnostic reagent or kit.

4. The use according to claim 3, It is characterized in that The expression level of SLC4A11 is reduced in patients with ovarian cancer who have a better prognosis.

5. The use according to claim 3, It is characterized in that The reagent for detecting the expression level of the SLC4A11 gene is selected from primers for specific amplification of the SLC4A11 gene; or probes for specific recognition of the SLC4A11 gene or its transcript; or antibodies specific to the SLC4A11 protein.

6. Application of SLC4A11 inhibitors in the preparation of drugs for the treatment of ovarian cancer.

7. The use according to claim 6, It is characterized in that The siRNA targeting the SLC4A11 gene.

8. The use according to claim 7, It is characterized in that The siRNAs are shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:

3.

9. Application of SLC4A11 inhibitors in the preparation of reagents, It is characterized in that The reagents are used for: a) inhibiting the proliferation of ovarian cancer cells; b) inhibiting the migration of ovarian cancer cells; c) inhibiting ovarian cancer cell invasion; or d) Promote apoptosis of ovarian cancer cells, The inhibitor is selected from antisense nucleic acids that use SLC4A11 protein or its transcript as target sequence and can inhibit its protein expression or gene transcription; or constructs that can express or form the antisense nucleic acid.

10. A pharmaceutical composition for treating ovarian cancer, It is characterized in that The pharmaceutical composition comprises an inhibitor of SLC4A11 and a pharmaceutically acceptable carrier.